Shares of telehealth platform and direct-to-consumer (D2C) personal care products provider Hims & Hers Health (NYSE: HIMS) fell 6.7% on Wednesday, Sept. 23, as investors continue to weigh the fallout from August’s disappointing earnings report and mounting legal pressure, including a securities class action filed earlier this month and an ongoing FTC lawsuit over alleged privacy and billing practices.
HIMS' year-to-date (YTD) loss is over 12%, including a nearly 26% loss from its YTD high on July 6.